Verified ComparisonLast updated: 14 April 2026
CJC-1295 + Ipamorelin vs Tesamorelin
The combination of CJC-1295 and ipamorelin targets both GHRH and ghrelin receptors, while tesamorelin is a standalone GHRH analog with approved medical use.
CJC-1295 + Ipamorelin
Growth Hormone
4.4/ 5
A
Tesamorelin
GH Releasing
4.4/ 5
A
Editor's note
Dual peptides offer dual-pathway synergy; tesamorelin has regulatory and clinical backing.
| Criterion | CJC-1295 + Ipamorelin | Tesamorelin |
|---|---|---|
| Mechanism | GHRH + GHS-R agonists (dual) | GHRH analog (single) |
| Synergy potential | High — dual pathways | Single pathway |
| Approved indication | None | HIV-related lipodystrophy |
| Clinical evidence base | Research literature | Approved-indication trials |
| Complexity | Requires two peptides | Single agent |
Frequently asked questions
Dual-pathway peptides offer complementary mechanisms; tesamorelin is a proven single agent.
Want to read the full reviews?